Scholars Central

Research articlePublished 25 Aug 2014

Switching to Iloperidone: An Omnibus of Clinically Relevant Observations from a 12-Week, Open-Label, Randomized Clinical Trial in 500 Persons with Schizophrenia

Authors: Leslie Citrome, Peter J. Weiden, Gus Alva, Ira D. Glick, Richard Jackson, Greg Mattingly, Farid Kianifard, Xiangyi Meng, Adam Winseck

Clinical Schizophrenia & Related Psychoses

Volume 9 · Issue 1 · Pages 183–195

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Objective: To describe secondary analyses from a 12-week, randomized, open-label trial where adult schizophrenia outpatients receiving risperidone, olanzapine, or aripiprazole were switched to iloperidone. Methods: Patients were randomized into two groups: one where the antecedent antipsychotic dose was titrated downwards to zero over 2 weeks (n=240), and the other group where the antecedent antipsychotic was abruptly stopped (n=260). Adaptations of the Clinical Global Impression scale were used to evaluate clinical changes. Other assessments included the reporting of adverse events (AEs), study discontinuation, body weight, and metabolic variables. Results: Improvement was steady throughout the study for both gradual- and immediate-switch groups starting at Week 1 and continuing through Week 12. Discontinuations due to AEs in the first 2 weeks of treatment were higher for the immediate-switch group compared with the gradual-switch group (10.8% vs. 5.4%, NNT 19, 95% CI 10–151). Fewer patients in the gradualswitch group experienced dizziness as an AE, whereas a higher percentage of patients in the immediate-switch group exhibited earlier onset of a therapeutic response within the first 2 weeks; both groups were comparable thereafter with low rates of dizziness and similar efficacy outcomes. Conclusions: Switching to iloperidone can be accomplished either with a gradual crossover or immediate discontinuation of the prior antipsychotic; however, the immediate-switch method is associated with greater proportion of initial dizziness. The observed outcomes are consistent with what has been previously reported regarding iloperidone’s favorable akathisia/EPS profile and modest impact on somnolence/ sedation, body weight, and metabolic variables.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Schizophrenia & Related Psychoses.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Schizophrenia & Related Psychoses
  • SubjectMental Health and Psychology
  • BylineArticles whose byline prints “Leslie Citrome”
  • BylineArticles whose byline prints “Peter J. Weiden”
  • BylineArticles whose byline prints “Gus Alva”
  • BylineArticles whose byline prints “Ira D. Glick”
  • BylineArticles whose byline prints “Richard Jackson”
  • BylineArticles whose byline prints “Greg Mattingly”
  • BylineArticles whose byline prints “Farid Kianifard”
  • BylineArticles whose byline prints “Xiangyi Meng”